Objectives: This study had five objectives: 1) to measure and compare total opioid use and number of opioid doses in patients treated with opioids versus ketamine in conjunction with opioids; 2) to measure pain scores up to 2 hours after presentation in the ED patient with pain, comparing standard opioid pain control to ketamine in conjunction with opioids; 3) to compare patient satisfaction with pain control using opioids alone versus ketamine in conjunction with opioids; 4) to monitor and compare side effects in patients treated with opioids versus ketamine in conjunction with opioids; and 5) to identify effect variation between different subgroups of patients, with the purpose of focusing future research. We hypothesized that low-dose ketamine, compared to placebo, as an adjunctive treatment to opioids would result in better pain control over 2 hours and greater patient satisfaction with pain control; further, this protocol will result in a lower opioid dosage over 2 hours.
P ain is a common complaint among patients presenting to the emergency department (ED), with one study reporting a prevalence of greater than 75%, [1] [2] [3] yet it has been reported that pain control in the ED is frequently suboptimal. 3, 4 Many variables contribute to this finding, including limited resources or lack of diligence for assessing and treating pain, side effect barriers to patients reporting pain (i.e., sedation, displeasure with side effects). 1, 3, 4 Opioid agonists are commonly used to treat patients in moderate to severe pain, but often have undesirable side effects. When applicable, excessive sedation can interfere with the patient's ability to report and subsequently the physician's ability to effectively manage pain. 5 The ability to reduce cumulative opioid doses, and achieve acceptable pain control, may limit undesired side effects and free up nursing resources by decreasing repeated dose administration. For these reasons, alternatives or adjuncts to opioid therapy are needed.
Ketamine is often used as a dissociative, amnestic medication during extremely painful procedures. 6 Additionally, ketamine has analgesic properties, and recent investigations have shown promise using subdissociating doses in a variety of settings for the control of acute pain. While a subdissociating dose alone is generally not effective for management of moderate to severe acute pain in emergency settings, [7] [8] [9] it has been shown to successfully improve pain when used in combination with opioid analgesia in a variety of settings. [10] [11] [12] [13] [14] Effects on pain control have been mixed. Low-dose ketamine in one prehospital study was shown to have an opioid-sparing effect at 30 minutes without affecting pain scores compared to placebo, 10 while in other studies pain scores were reduced compared to placebo. [13] [14] [15] Importance While ketamine has previously been shown to have an effect on opioid usage out to 120 minutes postadministration, the majority of ED-or prehospital-based studies have a much shorter time frame. [7] [8] [9] [10] Few prospective studies exist that have examined the effect of ketamine as an adjunct to opioid pain control in the ED setting over an extended period of time in a more general patient population with pain, and none that evaluated 120 minutes postadministration. Reducing the incidence of adverse side effects is always a desirable clinical improvement, as is the reduction of resources necessary to effectively treat a patient. If it were to be shown that ketamine could be used in conjunction with opioids to manage moderate to severe pain in the ED with a concurrent reduction in the requirement of volume and number of doses of opioid analgesics, this could provide an alternative treatment option. This may result in a better clinical experience for the patient and a reduced requirement for nursing resources to effectively manage the patient load.
Goals of This Investigation
We hypothesize that low-dose ketamine, compared to placebo, as an adjunctive treatment to opioids would result in better pain control over 2 hours and greater patient satisfaction with pain control; further, this protocol will result in a lower opioid dosage over 2 hours.
METHODS

Study Design and Setting
This was a randomized, double-blinded, placebo-controlled trial conducted in the ED at Carilion Roanoke Memorial Hospital, a medical school affiliated Level I trauma center and tertiary care referral center with a yearly census of over 90,000 visits.
Population
Subjects were a convenience sample of patients recruited between September 2013 and March 2015. Patients meeting inclusion criteria who presented during enrollment shifts were considered for inclusion in the study; however, there was not continuous coverage for enrollment. Patient screening, enrollment, and data collection were conducted by a member of the research team during dedicated research shifts in which the researcher had no additional clinical responsibilities. These were rotating shifts with equivalent distribution throughout the day and night and various days of the week, including weekends. Patients were identified for inclusion using real-time chart review; patients meeting age inclusion criteria, reporting pain equal to or greater than 6/10, and whose primary ED physician ordered intravenous (IV) opioid analgesia were eligible for inclusion in this study. Patients were first approached regarding potential inclusion at the time of first administration of IV opioid administration. Once identified for inclusion, the details of the study were discussed with the patient and they were asked to provide written, informed consent and were subsequently assigned through block randomization into one of two study groups. Randomization was determined using a table of random numbers, using a restricted randomization scheme to ensure roughly equal numbers in each group. This randomization schematic was created by pharmacy administration and not available to any member of the research team. Subjects were then assigned a subject number that did not indicate whether they were in the treatment or the control group. Inclusion and exclusion criteria are shown in Table 1 . Patients interested in participating were asked to complete a short questionnaire to demonstrate their understanding of the study. The patient questionnaire was developed based on the Aid to Capacity Evaluation. 17 Patients were required to score an 80% to be accepted as study subjects.
Study Protocol and Measurements
Patients received initial provider-determined treatment for their painful condition (recorded as "initial dose") before the informed consent process to ensure that treatment was not delayed. Patients were reassessed after 15 minutes and if, after the initial dose of analgesia, the patient reported pain ≥ 6/10 informed consent was obtained, as well as an initial NRS-11 score (T0), and a study number was assigned. Each study number was correlated with a syringe containing study drug (ketamine or normal saline), the identity of which was known only to pharmacy staff not participating in ED bedside care. Patients randomized to the ketamine group received 0.1 mg/kg of ketamine given over 1 minute, and those randomized to the control group received an equivalent volume of normal saline. The 0.1 mg/kg dose was chosen based on a combination of a review of the common dosing levels presented in the literature at the time of study inception and institutional limitations. Patients who reported pain < 6 were not included in the study. At 30-minute intervals, subjects were asked their level of pain or if they needed more pain control and were evaluated for the presence of side effects, as well as sedation as defined by Ramsay score of greater than 2. 18 Vital signs (as previously listed) were also recorded at this time. Repeat doses of pain medication were given as 0.05 mg/kg morphine or equivalent dose of opioid analgesic when requested by the subject, as long as the subject did not have a Ramsay score greater than 2. Infrequently, patients required doses of analgesia between time points; in these instances, medication choice and dosing were at the discretion of the provider so as not to impede patient access to pain relief nor provider clinical care. If the medication chosen was an opioid analgesic, that dose was recorded and included in the final opioid dose. Total opioid dose and number of repeat doses given at the end of 120 minutes were recorded. At each time interval, as well as at the end of 120 minutes (T120), patient satisfaction with pain control was recorded on the 4-point Likert scale, 19, 20 with 0 being "completely unsatisfied" and 3 being "very satisfied." A study period of 120 minutes was chosen based after a review of anesthesia literature, showing a clinical effect of ketamine on opioid consumption up to 120 minutes postadministration. 7, 10, 11 If care ended prior to T120, data were collected until the point at which they left the ED. 6. An inability to understand the NRS-11 pain measurement scale. 16 7. Presentation with headache or chest pain. 8. The condition of pregnancy (determined by date of last menstrual period; patients who are unsure whether or not they may be pregnant will receive point-of-care pregnancy testing). 9. A lack of decision-making capacity. 10. A pain score less than 6 on the NRS-11 scale. 11. A concern by the treating physician or study personnel of current or prior history of narcotic abuse, or other secondary gain. 12. Previously participated in the study.
Study drug preparation was handled by pharmacy personnel and overseen by an ED pharmacist. Both ketamine and placebo were prepared in 30-mL aliquots, placed in identical syringes, and labeled sequentially. Syringes were stocked in a Pyxis MedStation in the ED, which is accessible only to approved personnel and requires a validated fingerprint to access. At no point were the study coordinator, primary investigator, co-investigator(s), or research assistant(s) included in the preparation or stocking of study drugs. Patients, nurses, ED providers, research assistants, and investigators were all blinded to syringe contents. The list of study numbers and group assignments were maintained securely in the hospital pharmacy and available in the event of an adverse event. No subject's group assignment was revealed to any member of the research team prior to study conclusion and data analysis.
Outcomes
Data were recorded regarding patients' chief complaint/painful condition, number of prior visits for painful conditions, prior opioid use, initial pain level (as reported using the NRS-11 16 ), pain level throughout the study (collected at 30-minute intervals), satisfaction with their pain control (collected at 30-minute intervals, beginning at T30), requirement for repeat doses of opioid analgesic, total amount of opioid given, vital signs (blood pressure, heart rate, respiratory rate, and oxygen saturation determined by pulse oximetry), sedation level (measured by the Ramsay scale 18 ), any side effects experienced, age, race, sex, and other (nonopioid) medications/doses.
Data Analysis
Two primary outcomes were used: level of pain control and satisfaction with pain control. The study was powered however to address the primary outcome of pain control as satisfaction levels were conditional on the perceived pain level. The study was initially powered for analysis using two-sided independent sample t tests, requiring a randomized sample size of 110 to provide 80% power to detect, independently a difference of 1.5 on the NRS-11 scale and/or a difference of 0.5 on the 4-point Likert scale. However, the data collected were ultimately more suited to repeated measures analysis. The power analysis was repeated, and a randomized sample size of 88 (44 each arm) provided 80% power for a repeated measures analysis with a compound symmetry covariance structure. The amount of within-subject variance was unknown and therefore was widely estimated using a strong correlation of 0.9 within the covariance structure estimate. Mean pain scores for each treatment arm were estimated from a similar study, Beaudoin et al., 14 who assessed low-dose ketamine and morphine usage to improve pain relief. A constant between-subject variation of 4 (SD AE 2) was assumed for each time point. Again, this value was an exaggerated estimate of the variation witnessed in the study Beaudoin et al.. All other analyses conducted are considered exploratory/ descriptive as it relates to statistical power.
The comparison of treatment groups across patient demographics and opioid usage were implemented using Wilcoxon rank sum tests, chi-squared tests, and Fisher's exact test when cell sizes were small. Pain and satisfaction scores were compared across treatment groups using linear mixed models as a function of treatment, time, and their interaction and with a random intercept. The structure of variance within and between subjects is somewhat unknown and therefore whichever covariance structure provided the smallest AIC and BIC model fit statistics was applied. Structures considered included: compound symmetry, autoregressive (1), and unstructured. Upon visual inspection of the plotted pain level curves, a cubic time component was implemented for pain level scores due to the curvature of the scores across time. All statistical analysis was performed in SAS (version 9, SAS Institute Inc.).
This study was approved by the Carilion Clinic Institutional Review Board, with ClinicalTrials.gov trial identification number NCT02489630. Financial support for the study was provided by the Carolyn L. Kuckein research fellowship administered by the Alpha Omega Alpha Carolyn L. Kuckein Student Research Fellowship, the Carilion Clinic Department of Emergency Medicine, the Virginia Tech Carilion School of Medicine.
RESULTS
Characteristics of Study Subjects
The study flow diagram is shown in Figure 1 . A total of 271 patients met initial inclusion criteria during the times in which a study member was present and enrolling in the ED. Of these 271 patients, 106 were excluded (10 due to provider concern for secondary gain, three due to provider's unwillingness to participate, 92 due to medical exclusion criteria) and 47 declined to participate in a research study. One potential subject was not enrolled due to inability to pass the Decision-making Capacity and Comprehension Assessment. A total of 116 patients were randomized to treatment groups, with 53 receiving ketamine and 63 receiving placebo. Two patients were enrolled in the study, but were never given study drug because their time to dosing exceeded the maximum.
The demographic characteristics of the cohort are displayed in Table 2 . There were no statistically significant differences between the ketamine and placebo groups across any demographic variables. Of the 63 patients who received the placebo, 25 had pain level observations every 30 minutes up to 120 minutes, or "complete" observations. Of the 53 patients who received ketamine, 23 had complete observations. The most common chief complaint was abdominal pain (28 patients in the control group, 19 patients in the ketamine group), followed by flank pain (eight patients in each group) and musculoskeletal complaints such as hip or back pain. Further, patients were questioned on their prior use of opioid analgesia to treat their presenting complaint. Sixteen patients in the ketamine group and 14 patients in the placebo group reported use of opioid analgesia prior to presenting to the ED.
Mean pain scores with accompanying standard deviation (SD) bars at each time point for both treatments can be seen in Figure 2 . Pain scores in both groups decreased ≥ 3 by T30. When modeling pain scores as a function of time, treatment, and their interaction, the unstructured covariance matrix provided the smallest AIC and BIC statistics. The interaction between treatment and the cubic time component was insignificant (p < 0.05) and was removed from the model. Parameters were reestimated without interaction producing significant main effects (Table 3) . After time was adjusted for, ketamine patients had a 0.6512 (p = 0.0083) lower mean pain scores than placebo patients. Missing observations, not subjects, were excluded from the modeling analysis via the SAS procedure used to perform the modeling, PROC MIXED.
As noted in previous studies, clinically significant differences in NRS scale scoring varies along the scale;
smaller changes in reported values are correlated with clinical significance at the low (nearer to zero) end of the scale as opposed to the high (nearer to 10) end of the scale. 17 Therefore, it is difficult in this context to assign clinical significance to the difference in reported pain scores between groups, previous statistical analysis of the NRS scale indicates that these differences are more likely to be clinically significant over time, as reported pain scores decrease.
Patient satisfaction scores were initially similar for the ketamine group (mean AE SD = 2.09 AE 0.88) and the control group (mean AE SD = 2.27 AE 0.84) and remained similar over time (Figure 3) . The final mean (AESD) satisfaction score in the ketamine group was 2.66 (AE0.67) and 2.52 (AE0.50) in the control group. These scores were collected from patients beginning at T30 and prior to asking if the patient needed more pain medication. Twenty patients from the control group and 14 patients from the ketamine group reported a score of 3 ("extremely satisfied" with their pain control) throughout the study; one patient from the ketamine group and two people from the control group reported a score of 0 ("extremely dissatisfied" with their pain control) throughout the entire study. When modeling satisfaction scores, the interaction between treatment and time proved significant. Parameter estimates can be seen in Table 3 . A significant interaction suggests the relationship between satisfaction and ketamine patients is significantly different than the relationship between satisfaction scores and the placebo patients. Specifically, for every 30-minute increment, ketamine patients' mean satisfaction score was increasing by 0.183 points while the placebo patients' mean satisfaction score was only increasing by 0.07, a significant difference (p = 0.0287).
Similar findings were detected in the analysis for total opioid dose. The mean (AESD) initial opioid dose for the total cohort was 5.63 (AE2.51) mg morphine equivalent; the mean (AESD) initial opioid dose in the ketamine group was 5.41 (AE2.77) mg and in the control group was 5.83 (AE2.27) mg morphine equivalent. The difference in the mean initial opioid doses between the two groups was not statistically significant at the a = 0.05 level (p = 0.2182). The mean (AESD) total opioid dose in the ketamine group was 9.95 (AE5.83) mg morphine equivalent and in the control group was 12.81 (AE6.81) mg morphine equivalent. The Wilcoxon rank-sum test indicated that there was a statistically significant difference in total opioid dose between the two treatments (p = 0.02). Thirty-four patients in the control group received, under the protocol, one dose of additional analgesia, 13 required two doses, five required three doses and one required four doses of additional analgesia. Twenty-four patients in the ketamine group received, under the protocol, one dose of additional analgesia, nine required two doses, one required three doses, and one required four doses of additional analgesia ( Table 4) .
As noted in the above study protocol, the type and dose of rescue analgesia (medication requested by the subject at times other than at the prescribed time points) was determined by provider discretion, in an effort neither to impede patients' access to necessary analgesia nor to impede the providers' clinical practice. Only in three instances (one ketamine-group subject and two placebo-group subjects) was that analgesia administered in the form of opioids. These doses were recorded as repeat doses and included both in the rescue dose and total opioid dose tabulations. Further, five patients in the ketamine group received nonopioid rescue medication (four received toradol and one received acetaminophen). Six patients in the placebo group received nonopioid rescue medication (all six received ketorolac).
A total of seven study patients received procedural analgesia during the study period. One ketamine-group patient received regional anesthesia in the form of lidocaine. Two placebo-group patients received regional anesthesia in the form of 1% lidocaine without epinephrine, one received local anesthesia in the form of 0.5% bupivacaine, one received a topical application of 4% lidocaine/0.1% epinephrine/0.5% tetracaine, and one received propofol as procedural sedation for a shoulder reduction.
Twelve patients in the placebo group (19.0%) and 27 in the ketamine group (51%) reported side effects, shown in Table 5 . Subjects were directly observed by study personnel after study drug administration and monitored for immediate side effects. Most side effects resolved within 3 to 4 minutes of medication administration, and no patient had side effects lasting longer than 6 minutes. All patients were placed on monitoring prior to administration of study drug (continuous heart rate and SpO 2 %, interval blood pressure measurements); no patients experienced a clinically significant change in vital signs. Two patients (who did not initially report side effects) were withdrawn for excessive sedation as defined by a Ramsay score of 3, one from each study group. One of these subjects received only the initial provider-determined opioid dose and the study drug, and the other subject received the initial provider-determined dose, the study drug, and one weight-based repeat dose at the 30-minute time point. The latter patient's provider was comfortable with the subject's level of sedation, but the patient was withdrawn per the protocol requiring a Ramsay score ≤ 2. The study protocol was suspended and patients were placed under monitoring for 30 minutes, during which time no adverse outcomes were noted and no medical management of their sedation level was necessary. Both patients were discharged home from the ED by their provider. No patients required additional medical treatment for side effects or excessive sedation.
DISCUSSION
Low-dose ketamine has previously shown potential as an adjunct to stand-alone opioid treatment. [12] [13] [14] 21 In fact, a dose-response relationship has been established in the literature. Galinski et al. 12 established that a ketamine dose of 0.2 mg/kg was sufficient to reduce opioid usage by 25% at 30 minutes postadministration; however, they did not demonstrate a statistically significant reduction in patient-reported pain scores. More recently, Beaudoin et al.
14 published a randomized, double-blind, placebo-controlled study which showed an opioid-sparing effect. This study examined doses of both 0.3 and 0.15 mg/kg and found a more pronounced effect at the higher dose, along with increasing side effects.
Our results further underscore this dose-response relationship for pain score reduction. While there was a statistically significant difference in pain score reduction between the ketamine and control groups, it was a smaller difference than that reported in studies with higher ketamine doses. 13, 14 Mean total opioid dose was lower in the ketamine group versus the control group; this reduction in dose is similar to what was described by Galinski et al. at the higher dose of 0.2 mg/kg. 12 There was no statistically significant difference in levels of patient satisfaction with their pain control between the two study arms. While this nullifies our hypothesis that patients would profess greater satisfaction with the ketamine intervention, it is important to note that the patients in the ketamine arm also did not report less satisfaction with pain control, and satisfaction with pain control was equivalent between the two groups. Interestingly, patients in both groups reported increased satisfaction levels over the course of the study, despite the fact that the control group reported pain scores that equilibrated after 30 minutes. However, as previously mentioned, this conclusion must be viewed in light of the presence of the dedicated study investigator. Patients' responses may have been influenced not only by the effectiveness of their treatment, but also their view that the medical team was actively working to control the patient's pain.
The number of patients who required additional analgesia, or the total number of additional doses, was not analyzed for statistical significance; however, the number of subjects requiring additional doses was fewer in the ketamine group (36 vs. 53). The ketamine group also had fewer patients who required more than two additional doses. Five patients in the control group required three additional doses and one required four additional doses, whereas only one patient in the ketamine group required three doses and one required four doses. This may be related to the linear decrease in reported pain scores throughout the study by the subjects in the ketamine group. That is, patients who are experiencing a gradual reduction in pain over time may be less likely to request additional medication than those whose pain levels declined and maintained, but did not perceive continued improvement in pain control.
While the patients in the ketamine group experienced a higher incidence of certain side effects (nausea, light-headedness or dizziness, itching, nystagmus, tinnitus), there were no adverse or unexpected events in either treatment group, nor did any patient require additional monitoring or clinical intervention due to their treatment. Further, no side effect lasted longer than 6 minutes. Patients in the placebo group experienced a higher incidence of dry mouth and disorientation. The difference in side effect frequencies in this study are more significant than those seen in other studies; however, side effects in this study were assessed immediately after medication administration, as opposed to some duration after administration. Given that no side effect lasted longer than 6 minutes, these differences would appear much less significant if measured at 15 or 30 minutes postadministration, as done in other studies. 12, 13 Demographically, the study groups were comparable on the basis of age, sex, race, weight, type of initial ACADEMIC EMERGENCY MEDICINE • June 2017, Vol. 24, No. 6 • www.aemj.org opioid received, and chief complaint. Further, the number of patients who completed the entire 120-minute time period was similar between the two groups. Side effects experienced by subjects appear to be more frequent in the ketamine group than the control group. All side effects experienced were previously anticipated and commonly observed events after the administration of ketamine; there were no unexpected adverse events. Of the patients who reported side effects, only one patient complained that they were dissatisfied and might reconsider joining the study if they were to be able to make the choice again. Patients experiencing side effects were observed by the enrolling investigator until the side effects abated. No instance of side effects occurring at the time of study drug administration lasted longer than 6 minutes, and no study subject required medical treatment for any side effect.
LIMITATIONS
This study was conducted in a busy ED in the general patient population, without special conditions, locations, or providers for study patients. The cohort includes subjects with chronic pain and long-term outpatient opioid use, as well as patients with new-onset acute pain; it is possible that the former patient population may react quite differently to the adjunctive ketamine usage than the latter.
The protocol provides more frequent reassessments of pain and a more codified and controlled method of treating pain than what commonly exists in an ED setting. The environment of the ED allows for less precise control of certain other variables, such as timing of medication administration and specific opioids prescribed, which may have an effect on applicability of study results in everyday practice.
Further complicating these particular data is not just the subjective nature of patient-reported values, but also the presence of a dedicated study investigator giving the appearance of closer, more personalized care, which may have biased the subjects' evaluation of how satisfied they were with their pain control (both in the control and in the ketamine groups). A more valuable comparison may be that between satisfaction levels of study patients and nonenrolled patients, who may feel that they are receiving less individualized attention and less personalized pain control.
In all cases, efforts were made to record data points as close to the specified time (30, 60, 90, or 120 minutes) as possible and to dose study drugs expeditiously (within 30 minutes of initial opioid administration, or the "initial" dose, and within 10 minutes of request for doses of additional analgesia). Two patients were withdrawn from the study prior to study drug administration because the administration had been delayed well beyond the prescribed 30-minute window.
The Ramsay scoring system was chosen for assessment of subjects' sedation level; however, it is acknowledged that an elevated Ramsay score may or may not correlate to a clinically significant and/or unsafe level of sedation. As such, this may have resulted in the unnecessary withdrawal of the two subjects whose Ramsay scores were above the proscribed level of 2; however, it was felt to be a simple and functional tool for assessment in the context of this study. The study organizers preferred to withdraw a patient unnecessarily rather than risk oversedation of a study subject.
Each patient's initial opioid dose was determined by their respective providers prior to the patient being screened for study enrollment. Additional analgesia, which was requested at any predetermined time point from the study investigator (i.e., at T30, T60, T90, or T120), was protocolized and weight-based. However, in a few instances, patients required additional analgesia between time points. In these instances, the prescribed medication and dose was at the provider's discretion and included in the analysis.
While the selected dose of ketamine in this study is lower than that of some studies that have been published since the inception of our work, we were still able to see a response at this dosage and, in fact, able to further underscore the dose-response relationship seen in the literature as a whole. It would be interesting to see, in further work, if the dose-response relationship would continue to be supported with higher doses of ketamine in a study of our current design.
There were, infrequently, times when a time point was missed due to the patient being out of the department (for CT scans, ultrasounds, or x-rays, for instance) or undergoing a procedure. The analytical methods used accommodated for these missing data points.
CONCLUSIONS
In conclusion, low-dose ketamine was found to be an effective adjunct to opioid analgesia for the treatment of acute pain in the ED. Patients treated with low-dose ketamine in addition to their opioid analgesia reported greater reduction in pain over time and similar satisfaction with their treatment to those treated with placebo in addition to their opioid analgesia. While there was a greater incidence of side effects in the ketamine group, the side effect profile for the treatment appears to be tolerable, and no additional clinical resources were required to manage the observed side effects. Additionally, fewer patients in the ketamine group required subsequent doses of analgesia during the observation period. The burden of medication dosing, requiring physicians to order medication doses and nurses to obtain, administer, and document the medication dose, is not insignificant. While further studies would be necessary to quantify the value of the reduced dosing requirements, these outcomes could be significant for their impact on the ED providers and patients, enabling more effective pain management, less demand on ED staff, and a reduction in opioid dosage requirements.
